STAT+: Axsome drug reduces agitation in Alzheimer’s patients, data show
A drug developed by Axsome Therapeutics significantly reduced a common side effect of Alzheimer’s disease…
Category: biotechnology
STAT+: FDA approves a gene therapy for the inherited bleeding disorder hemophilia B
The Food and Drug Administration on Tuesday approved the first gene therapy to treat people…
STAT+: Northwest Bio study of cancer vaccine still falls short
Northwest Biotherapeutics tried again, but its experimental treatment for brain cancer still falls short. Last…
STAT+: Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases
Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs…
mRNA revolutionized the race for a Covid-19 vaccine. Could cancer be next?
This story has been adapted from the STAT Report “The future of messenger RNA: Covid-19…
STAT+: Biosplice, once the most valuable biotech startup, sees a pair of osteoarthritis trials fail
Biosplice’s bid to transform the treatment of everything from arthritis to cancer ran into a…
mRNA drugs with a built-in ‘copy machine’ could lead to safer, more effective therapies
This story has been adapted from the STAT Report “The future of messenger RNA: Covid-19…
Listen: Roche’s failure, Eisai’s success, and a live AMA
How do Alzheimer’s drugs even work? Can biotech people bake? And do we even like…
STAT+: Editas, facing another setback, halts development on first clinical CRISPR program
Editas Medicine, one of the small handful of original CRISPR companies, announced Thursday it is…
STAT+: ‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming
NUTLEY, N.J. — A once-in-a-generation medicine was built on more than two decades of regret….
The scientist behind Pfizer’s Covid vaccine says a flu pandemic is only a matter of time
BOSTON — Even after leading the charge combating the worst pandemic in a century, vaccine…
STAT+: Cooling demand for new lab space in Boston could be good news for biotech companies
Amid a bumpy few years for development in Boston, the business of building lab space…
STAT+: Thrive founders launch new blood testing startup to spot when cancer returns
Among the many anxiety-inducing issues faced by cancer patients is the question of whether the…
Covid-19 vaccines were a success, but mRNA still has a delivery problem. Two startups have an unorthodox solution
This story has been adapted from the STAT Report “The future of messenger RNA: Covid-19…
.jpg)
STAT+: ‘If this works, it changes everything’: Altos Labs founders lay out plan to reverse disease
BOSTON — The executives behind Altos Labs would really, really like people to stop saying…
Perfection is too high a bar for CRISPR treatments, says STAT Biomedical Innovation Award winner David Liu
BOSTON — In science journalism, there’s a well-worn technique reporters reach for when they’re interviewing…
STAT+: 5 looming questions about the exodus of young life scientists from academia
The unprecedented departure of young life science Ph.D.s and postdocs from academia raises all sorts…
STAT+: Immunogen wins FDA approval for targeted medicine to treat advanced ovarian cancer
The Food and Drug Administration on Monday approved a new treatment for patients with advanced…
STAT+: Despite higher dose, Stoke Therapeutics drug not active enough against childhood epilepsy
Stoke Therapeutics said Monday that a higher dose of its experimental drug for epilepsy reduced…
Moderna data suggests new Covid booster is more effective against Omicron variants
New data indicate Moderna’s Covid bivalent booster may be more effective against currently circulating Omicron…
STAT+: Boom and bust: Whose biotech VC assets have grown and shrunk the most?
Money has gushed into the biotech industry over the last couple of years, as the…
STAT+: Roche’s experimental Alzheimer’s treatment fails to slow cognitive decline across two clinical trials
Roche reported negative results Monday from a pair of clinical trials investigating an antibody treatment…
STAT+: Head of MassBio trade group is out after serving just over a year
Barely a year after he was named head of the Massachusetts Biotechnology Council, former state…
STAT+: Biogen’s new CEO, clear-eyed about company’s challenges, prepares to take the reins
Christopher Viehbacher, who will start as Biogen’s CEO on Monday, knows that running Biogen may…
Listen: Biogen’s new CEO, how the midterms affect science, & a biotech bankruptcy
How can Biogen right the ship? What happened to that “red wave”? And what can…
STAT+: PACT Pharma’s personalized cancer treatments, powered by CRISPR, clear early safety hurdles
Two years ago, researchers at the University of Pennsylvania showed for the first time that…
STAT+: Biogen appoints former Sanofi executive Christopher Viehbacher as CEO
Biogen named Christopher Viehbacher, who formerly ran the French drug giant Sanofi, as its new…
STAT+: For its first two medicines, EQRx abandons its bold strategy to lower drug prices
Changing the way cancer drugs are priced in the U.S. is apparently even harder than…
STAT+: Jeff Jonas leaves Sage Therapeutics to launch biotech incubator
Longtime Sage Therapeutics executive Jeff Jonas is leaving the biotech company to launch a biotech…
STAT+: FDA panel votes against Veru’s drug for severe Covid
An FDA advisory panel voted 5-to-8 to recommend rejecting a new drug for patients hospitalized…
STAT+: Clovis Oncology warns of likely bankruptcy filing following years of scandal and financial losses
Clovis Oncology, a maker of cancer drugs, warned Wednesday that it will likely file for…
STAT+: Shares of Merrimack, a dormant drugmaker, soar after cancer drug succeeds in trial
Shares of Merrimack Pharmaceuticals, a shuttered drug company with no employees or any active research…
STAT+: Faze Medicines, a biotech focused on neurological diseases, is shutting down
A biotech company that hoped to use cell biology to address neurological disorders is shutting…
STAT+: J&J’s Mammen out of the running for Biogen CEO post
Biogen is mulling new options in its search for a CEO after talks with a…
STAT+: FDA places clinical hold on Verve Therapeutics gene-edting treatment
Verve Therapeutics said Monday that its experimental gene-editing treatment for a common form of heart…
STAT+: FDA approval decision for Apellis Pharma’s eye disease drug delayed to review more clinical data
Apellis Pharmaceuticals said Thursday that submission of additional clinical data to the Food and Drug…
Listen: How the biotech revolution could come apart at the seams
What’s the atom bomb of biology? Why don’t we run better clinical trials? And how…
STAT+: A live chat about ‘biology’s century’
CRISPR, gene therapy, CAR-T, and Covid vaccines. Science is advancing at a blistering pace. But…
Here’s why we’re not prepared for the next wave of biotech innovation
The first time I remember hearing the words “biology’s century,” it was a sales pitch….
STAT+: Weight-loss drug had dramatic effect in adolescents with obesity, study finds
A blockbuster weight-loss medicine led to dramatic effects for adolescents diagnosed with obesity, a result…
STAT+: Novel solution to biotech’s market valuation woes: Just give the cash back
It’s tough times to be a public biotech, especially a small one. As the market…
STAT+: Biotech company seeks to overcome hurdles to develop flu vaccine skin patch
In the future, getting a flu shot might be as easy as opening the mailbox…
STAT+: A turnaround for Editas Medicine, a CRISPR laggard, hinges on updates on key treatments
Editas Medicine’s new leadership team on Wednesday reiterated a promise to deliver clinical updates on…
Listen: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms
Can Covid denialism get you elected? How is the music business like biotech investing? And…
STAT+: A new suite of RNA-sensing tools could help scientists target cancerous cells, and much more
Sure, you’ve heard of CRISPR. But it’s 2022. The acronym you need to know now…
Biotech’s newest odd couple: A pharma insider and a music maven launch a health care VC
D.A. Wallach’s first meeting with his business partner could have been the setting of a…
STAT+: Pacific Biosciences, known for niche DNA sequencing, looks to rival Illumina with new product launch
Pacific Biosciences, a Menlo Park, Calif., firm best known for its niche approach to DNA…
STAT+: Normunity launches with $65 million to unleash the immune system on tumors
Our best weapon against cancer may already live inside us — it just needs a…
STAT+: Inside Michelle McMurry-Heath’s departure from BIO: Firings, internal clashes, and a pivotal job review
WASHINGTON — Only two years ago, Michelle McMurry-Heath was named chief executive of BIO, the…
‘Front of the line’: For Alzheimer’s patients in successful trial, a feeling of gratitude
When the news came out last month that an experimental Alzheimer’s therapy succeeded in a…